Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Guardant Health (GH)
NASDAQ:GH
Guardant Health (GH) Stock Price & Analysis
1,696 Followers
GH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$16.04 - $41.06
Previous Close$16.16
Volume443.02K
Average Volume (3M)2.00M
Market Cap
$2.11B
Enterprise Value$2.23B
Total Cash (Recent Filing)$1.17B
Total Debt (Recent Filing)$1.33B
Price to Earnings (P/E)-3.8
Beta1.73
Next Earnings
May 02, 2024EPS Estimate
-$0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.28
Shares Outstanding121,712,724
10 Day Avg. Volume2,663,014
30 Day Avg. Volume1,998,457
Standard Deviation0.15
R-Squared0.09
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)15.18
Price to Sales (P/S)13.39
Price to Cash Flow (P/CF)-7.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.96
Enterprise Value/Gross Profit2.82
Enterprise Value/Ebitda-5.03
Forecast
1Y Price Target
$38.13Price Target Upside131.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Guardant Health News
PremiumCompany Announcements
Guardant Health Revises Co-CEOs’ Compensation and Incentives
Bulls Say, Bears Say
Bulls Say
Financial ManagementManagement strategies aimed at reducing annual cash burn may lead to a stronger financial profile and potentially uplift Guardant Health's stock value.
Market VisibilityGuardant Health's recent publications in esteemed journals and media coverage could enhance the recognition and credibility of their non-invasive cancer screening technology.
Regulatory MilestonesAnticipated FDA approval and subsequent CMS reimbursement for Guardant Health's innovative cancer screening product could serve as significant growth drivers for the company.
Bears Say
Financial RisksCompany's screening business expected to burn significant cash in 2024, posing a risk to financial stability.
Pipeline UncertaintyDespite the strategic options for Shield CRC, management has signaled a willingness to abandon the program if it underperforms, which could imply uncertainty around this pipeline asset.
Regulatory ChallengesGH reported a delay of the FDA AdCom to late due to the added time needed to get enough committee members for the meeting.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
GH FAQ
What was Guardant Health’s price range in the past 12 months?
Guardant Health lowest stock price was $16.04 and its highest was $41.06 in the past 12 months.
What is Guardant Health’s market cap?
Currently, no data Available
When is Guardant Health’s upcoming earnings report date?
Guardant Health’s upcoming earnings report date is May 02, 2024 which is in 13 days.
How were Guardant Health’s earnings last quarter?
Guardant Health released its earnings results on Feb 22, 2024. The company reported -$1.58 earnings per share for the quarter, missing the consensus estimate of -$0.862 by -$0.718.
Is Guardant Health overvalued?
According to Wall Street analysts Guardant Health’s price is currently Undervalued.
Does Guardant Health pay dividends?
Guardant Health does not currently pay dividends.
What is Guardant Health’s EPS estimate?
Guardant Health’s EPS estimate is -$0.87.
How many shares outstanding does Guardant Health have?
Guardant Health has 121,712,720 shares outstanding.
What happened to Guardant Health’s price movement after its last earnings report?
Guardant Health reported an EPS of -$1.58 in its last earnings report, missing expectations of -$0.862. Following the earnings report the stock price went down -12.797%.
Which hedge fund is a major shareholder of Guardant Health?
Among the largest hedge funds holding Guardant Health’s share is Deerfield Management Company, LP. It holds Guardant Health’s shares valued at 21M.
---
Guardant Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.13 (131.79% Upside)
$38.13 (131.79% Upside)
Blogger Sentiment
Bullish
GH Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 722.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $39.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 5.6%
Last 30 Days ▲ 5.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.04%
12-Months-Change
Fundamentals
Return on Equity
-438.12%
Trailing 12-Months
Asset Growth
10.96%
Trailing 12-Months
Company Description
Guardant Health
Guardant Health, Inc. is a precision oncology company, which engages in provision of precision oncology testing and development services. It focuses performing blood tests, vast data sets, and advanced analytics to conquer cancer. The company was founded by Helmy Eltoukhy and AmirAli H. Talasaz in 2012 and is headquartered in Redwood City, CA.
---
GH Company Deck
---
GH Earnings Call
Q4 2024
0:00 / 0:00
---
GH Revenue Breakdown
91.19% Precision oncology testing
8.81% Development services and other
---
GH Stock 12 Months Forecast
Average Price Target
$38.13
▲(131.79% Upside)
Technical Analysis
Best Analysts Covering GH
1 Year
1 Year Success Rate
4/24 ratings generated profit
1 Year Average Return
-20.38%
reiterated a buy rating 2 months ago
Copying Mark Massaro's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -20.38% per trade.
---